Most Clicked StoriesMore >


Merck unit, Sutro sign antibody-drug development pact worth over $298M

BIO SmartBrief | Sep 18, 2014

Merck KGaA unit EMD Serono and Sutro Biopharma agreed to partner on the development of antibody drug conjugates for cancer and other targets using the latter's cell-free synthesis platforms. The agreement entitles Sutro to an undisclosed upfront fee and up to $298 million in milestone fees plus sales royalties. Boston Globe (tiered subscription model), The (09/17) American City Business Journals (09/17)


AstraZeneca-Lilly's Alzheimer's drug pact could be worth $500M

BIO SmartBrief | Sep 17, 2014

Gilead licenses hep C drug Sovaldi to 7 Indian generic-drug firms

BIO SmartBrief | Sep 16, 2014

Greenwood: Increased offering ceiling under JOBS Act will help biotechs

BIO SmartBrief | Sep 19, 2014

Stem cell research offers hope, hype

BIO SmartBrief | Sep 17, 2014

Regeneron drug wins FDA breakthrough status for diabetic retinopathy

BIO SmartBrief | Sep 18, 2014

NIH gives $64 million to support development of cell signature network

BIO SmartBrief | Sep 16, 2014

Roche's advanced macular degeneration drug entering late-stage trials

BIO SmartBrief | Sep 16, 2014

NovaBiotics' cystic fibrosis drug wins orphan status from FDA

BIO SmartBrief | Sep 17, 2014

AstraZeneca-Nektar's opioid-induced-constipation drug gets FDA nod

BIO SmartBrief | Sep 17, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Housing & registration open for the BIO Pacific Rim Summit

BIO SmartBrief | Sep 22, 2014

Summer 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Sep 19, 2014

Registration is open for the BIO Investor Forum!

BIO SmartBrief | Sep 18, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Sep 17, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Sep 16, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more